Protagonist Therapeutics Sees Positive Topline Results in JNJ-2113 Trial
08 Marzo 2023 - 8:05AM
Dow Jones News
By Chris Wack
Protagonist Therapeutics Inc. said Tuesday it saw positive
topline results from its collaboration with Janssen Biotech Inc. in
a Phase 2b clinical trial evaluating the oral Interleukin-23
receptor antagonist peptide JNJ-2113 in patients with
moderate-to-severe plaque psoriasis.
The company said data from the 255-patient study showed that
JNJ-2113 achieved the study's primary efficacy endpoint, with a
statistically significant greater proportion of patients who
received JNJ-2113 achieving a 75% improvement in skin lesions as
measured by the Psoriasis Area and Severity Index at Week 16 in all
five treatment groups.
A clear dose response was observed across an eight-fold dose
range. Treatment was well tolerated, with no meaningful difference
in frequency of adverse events across treatment groups versus
placebo.
The Phase 2b trial was designed to assess the efficacy and
safety of JNJ-2113 in patients with moderate-to-severe plaque
psoriasis. It is a randomized study that evaluated three once-daily
dosages and two twice-daily dosages of JNJ-2113 taken orally.
JNJ-2113 was discovered and is being developed pursuant to the
license and collaboration agreement between Protagonist and Janssen
Biotech, Inc., one of the Janssen Pharmaceutical Companies of
Johnson & Johnson.
Protagonist shares were up 19%, to $18.13, in premarket
trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 07, 2023 08:37 ET (13:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Protagonist Therapeutics (NASDAQ:PTGX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Protagonist Therapeutics (NASDAQ:PTGX)
Storico
Da Set 2023 a Set 2024